Galena Biopharma Initiates Enrollment in Phase 1/2 Trial for Folate Binding Protein (E39) Targeted Peptide Vaccine in Ovarian and Endometrial Cancer Patients - MarketWatch Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, February 15, 2012

Galena Biopharma Initiates Enrollment in Phase 1/2 Trial for Folate Binding Protein (E39) Targeted Peptide Vaccine in Ovarian and Endometrial Cancer Patients - MarketWatch



0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.